Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study
Open Access
- 26 September 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (8) , 900-907
Abstract
In the setting of percutaneous coronary intervention (PCI), due to a paucity of data, the optimal dose of aspirin is uncertain. We evaluated the safety of different doses of aspirin after PCI. In the PCI-CURE study, 2658 patients with acute coronary syndromes undergoing PCI were stratified into three aspirin dose groups ≥200 mg (high, n = 1064), 101–199 mg (moderate, n = 538), and ≤100 mg (low, n = 1056). For efficacy, the moderate- (7.4%) and high-dose groups (8.6%) had similar rates of cardiovascular death, myocardial infarction, or stroke compared with the low-dose group (7.1%). For safety, major bleeding was increased with high-dose aspirin [3.9, 1.5, and 1.9% in the high-, moderate-, and low-dose groups; hazard ratio (HR) of high vs. low dose 2.05 (95% CI 1.20–3.50, P = 0.009]. The net adverse clinical events (death, MI, stroke, major bleeding) favoured low-over high-dose aspirin (8.4 vs. 11.0%, HR 1.31, 95% CI 1.00–1.73 P = 0.056). In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance.Keywords
This publication has 27 references indexed in Scilit:
- Aspirin Dose for the Prevention of Cardiovascular DiseaseJAMA, 2007
- Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary SyndromesCirculation, 2003
- Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular DiseaseCirculation, 2003
- The way I see it: House officers need formal career developmentBMJ, 2002
- Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trialThe American Journal of Cardiology, 2001
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingNew England Journal of Medicine, 1998
- Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.Circulation, 1993
- Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery diseaseThe Lancet, 1990
- Aspirin, Sulfinpyrazone, or Both in Unstable AnginaNew England Journal of Medicine, 1985
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983